• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24124 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2009     NIHR Horizon Scanning Centre (NIHR HSC) Ridaforolimus for unresectable locally advanced and metastatic soft tissue and bone sarcoma - maintenance therapy
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rifaximin (Xifaxanta®)
2015     National Institute for Health and Care Excellence (NICE) Rifaximin for preventing episodes of overt hepatic encephalopathy. NICE technology appraisal guidance 337
2019     Agency for Care Effectiveness (ACE) Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2015     NIHR Health Services and Delivery Research programme Right cot, right place, right time: improving the design and organisation of neonatal care networks – a computer simulation study
2014     NIHR Horizon Scanning Centre (NIHR HSC) Rigosertib for higher risk myelodysplastic syndromes – second and subsequent line
2009     NIHR Horizon Scanning Centre (NIHR HSC) Rilonacept for cryopyrin associated periodic syndromes
2012     NIHR Horizon Scanning Centre (NIHR HSC) Rilonacept for gout
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rilpivirine (Edurant®)
1997     Wessex Institute for Health Research and Development (WIHRD) Riluzole for motor neurone disease
1996     Scottish Health Purchasing Information Centre (SHPIC) Riluzole for motor neurone disease. Briefing note
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Riluzole for the treatment of amyotryophic lateral sclerosis: an assessment of clinical efficacy and safety
2023     National Institute for Health and Care Excellence (NICE) Rimegepant for preventing migraine. NICE technology appraisal guidance 906
2023     National Institute for Health and Care Excellence (NICE) Rimegepant for treating migraine. NICE technology appraisal guidance 919
2007     NIHR Horizon Scanning Centre (NIHR HSC) Rimonabant (Acomplia) for type 2 diabetes
2004     NIHR Horizon Scanning Centre (NIHR HSC) Rimonabant for smoking cessation, weight loss and cardiovascular risk factors of overweight/obesity - horizon scanning review
2009     NIHR Health Technology Assessment programme Rimonabant for the treatment of overweight and obese people
2015     NIHR Horizon Scanning Centre (NIHR HSC) Rindopepimut for EGFRvIII positive glioblastoma multiforme - first line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Riociguat (Adempas — Bayer HealthCare) indication: chronic thromboembolic pulmonary hypertension
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Riociguat (Adempas®)
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Riociguat (Adempas®)
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Riociguat for the treatment of pulmonary hypertension
2023     National Institute for Health and Care Excellence (NICE) Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments. NICE technology appraisal guidance 881
2023     National Institute for Health and Care Excellence (NICE) Risankizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 888
2022     National Institute for Health and Care Excellence (NICE) Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 803
2019     National Institute for Health and Care Excellence (NICE) Risankizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 596
2024     National Institute for Health and Care Excellence (NICE) Risankizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 998
2021     National Institute for Health and Care Excellence (NICE) Risdiplam for treating spinal muscular atrophy. NICE technology appraisal guidance 755
2013     NIHR Health Technology Assessment programme Risk Adjustment In Neurocritical care (RAIN) - prospective validation of risk prediction models for adult patients with acute traumatic brain injury to use to evaluate the optimum location and comparative costs of neurocritical care: a cohort study
2007     Andalusian Health Technology Assessment Area (AETSA) Risk adjustment systems in health services assessment
2001     Health Council of the Netherlands Gezondheidsraad (GR) Risk assessment of DON (deoxynivanol) in grain products - systematic review, expert panel
1995     Health Council of the Netherlands Gezondheidsraad (GR) Risk assessment of manual lifting
2008     Institute of Health Economics (IHE) Risk assessment tools for predicting recidivism of spousal violence
2014     Agency for Healthcare Research and Quality (AHRQ) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. preventive services task force recommendation
2020     NIHR Health Technology Assessment programme Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model
2007     New Zealand Health Technology Assessment (NZHTA) Risk factors for breast cancer in women: a systematic review of the literature
2010     Penn Medicine Center for Evidence-based Practice (CEP) Risk factors for complications of percutaneous coronary intervention
2014     Penn Medicine Center for Evidence-based Practice (CEP) Risk factors for high resource utilization in patients with sickle cell disease
2011     Penn Medicine Center for Evidence-based Practice (CEP) Risk factors for hospital readmission
2018     Health Information and Quality Authority (HIQA) Risk factors for inclusion as criteria within the clinical guideline on risk classification during pregnancy: a modified Delphi study
2018     Penn Medicine Center for Evidence-based Practice (CEP) Risk Factors for Surgical Site Infection and Infection Prevention in Elective Spine Surgery
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Risk factors to consider for extended anticoagulant therapy: a review of guidelines
2019     Health Information and Quality Authority (HIQA) Risk in pregnancy — systematic review of economic literature.
1996     Health Council of the Netherlands Gezondheidsraad (GR) Risk is more than just a number
2005     Alberta Heritage Foundation for Medical Research (AHFMR) Risk management for health technology assessment programs
2015     NIHR Health Services and Delivery Research programme Risk modelling for quality improvement in the critically ill: making best use of routinely available data
2003     Centre for Clinical Effectiveness (CCE) Risk of cerebral herniation due to lumbar puncture in children with suspected meningitis
2000     Centre for Clinical Effectiveness (CCE) Risk of infection in patients with femoral fractures who experience delays in surgery of more than 12 hours
1997     Health Council of the Netherlands Gezondheidsraad (GR) Risk profiles for HIV-positive individuals
2018     NIHR Health Technology Assessment programme Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2018     NIHR Health Technology Assessment programme Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2020     NIHR Health Technology Assessment programme Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT
2013     HAYES, Inc. Risk-reducing (prophylactic) mastectomy
2021     NIHR Public Health Research (PHR) programme RISKIT-CJS Pragmatic randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a multi-component intervention to reduce substance use and risk-behaviour in adolescents engaged with the criminal justice system
2016     NIHR Health Technology Assessment programme Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records
2013     The HTA Center of the Stockholm County Council/Gotland Risks associated with planned home delivery for nulliparous women
2005     Health Council of the Netherlands Gezondheidsraad (GR) Risks of alcohol consumption related to conception, pregnancy and breastfeeding
2007     Health Council of the Netherlands Gezondheidsraad (GR) Risks of exposure to ionising radiation
2000     Health Council of the Netherlands Gezondheidsraad (GR) Risks of folic acid fortification
1996     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Risks of occupational anaesthetic gas exposure for the pregnant woman and the fetus - systematic review
2009     NIHR Horizon Scanning Centre (NIHR HSC) Risperidone long-acting injection (Risperdal Consta) for prevention of recurrent episodes in bipolar 1 disorder
2024     National Institute for Health and Care Excellence (NICE) Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE technology appraisal guidance 958
2009     HAYES, Inc. Rituxan (Genentech Inc. and Biogen Idec Inc.) for Graft-Versus-Host Disease
2011     HAYES, Inc. Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for Chronic Lymphocytic Leukemia(CLL)
2010     HAYES, Inc. Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for multiple sclerosis
2009     HAYES, Inc. Rituxan (rituximab) (Genentech Inc. and Biogen Idec Inc.) for rheumatoid arthritis refractory to methotrexate and/or tumor necrosis factor (TNF) inhibitors
2010     HAYES, Inc. Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for systemic lupus erythematosus
2000     Alberta Heritage Foundation for Medical Research (AHFMR) Rituxan(R) (rituximab)
2004     NIHR Health Technology Assessment programme Rituximab (MabThera(R)) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation
2011     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
2011     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
2007     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for chronic lymphocytic leukaemia
2007     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (Mabthera) for non-Hodgkin’s lymphoma – first line maintenance therapy
2003     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for rheumatoid arthritis - horizon scanning review
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rituximab (MabThera®)
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia
2009     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (Rituxan/MabThera) for the first- and second-line treatment of chronic lymphocytic leukaemia
2002     NIHR Health Technology Assessment programme Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Rituximab biosimilars
2004     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab for 1st line low-grade non-Hodgkin's lymphoma - horizon scanning review
2002     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab for aggressive B-cell lymphoma - horizon scanning review
2003     Quality Improvement Scotland (NHS QIS ) Rituximab for aggressive non-Hodgkin's lymphoma
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical and cost-effectiveness
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for non-hodgkin's lymphoma: a review of the clinical and cost- effectiveness and guidelines
2006     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for rheumatoid arthritis
2010     NIHR Health Technology Assessment programme Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma
2011     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma. NICE technology appraisal guidance 226
2009     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of chronic lymphocytic leukaemia. NICE technology appraisal guidance 174
2012     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of stage III-IV follicular lymphoma. NICE technology appraisal guidance 243
2012     NIHR Health Technology Assessment programme Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation
2009     NIHR Health Technology Assessment programme Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
2006     Quality Improvement Scotland (NHS QIS ) Rituximab for the treatment of follicular lymphoma
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for the treatment of primary membranous nephropathy
2010     National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia. NICE technology appraisal guidance 193
2009     NIHR Health Technology Assessment programme Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
2008     Quality Improvement Scotland (NHS QIS ) Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
2008     National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. NICE technology appraisal guidance 137
2010     NIHR Health Technology Assessment programme Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
2009     NIHR Health Technology Assessment programme Rituximab for the treatment of rheumatoid arthritis